For example, inserting the LS (M428L, N434S) mutation into anti-vascular endothelial growth factor (VEGF) IgG1 Bevacizumab greatly extended mAb half-life by approximately four fold, resulting in increased anti-tumor activity56. The gene discussed is VEGFA; the disease is neoplasm.